Yeah exactly: that's why I call his piece "self-contradictory," b/c he says sell while all the stats he quotes confirm significant growth and %'s of growth. Only neg. is current lower cash b/c of their trials and expenses but based on growth and gross revenue this bodes extremely well for GALE and combined with the almost 1/4 short float that has to cover, rates a buy to many incl. big institutions.
It's mainly the decrease in PPS incl. residual from AF's hit piece that makes him see it as a sell right now.
Wish they muzzled AF but I doubt it frankly -- maybe they just realized that everyone sees thru him and hates him so much that they are letting someone else take a turn up at bat against GALE, but soon as this price soars again watch for AF's ugly mug to reappear.
Aferiat isn't personally disgusting b/c he isn't outright lying like AF claiming that something labeled an AD is "faux." He's just reflecting that the market has been wavering on GALE largely b/c of short attacks and of course he can't point to fellow Street contributor AF as a main cause.
We're way overdue for an analyst upgrade!
Look what happened to Achilleon, soared $1.50 overnight and next day on an upgrade, even after buyout rumors were largely debunked -- would feel so nice to see that GREEN in our accounts overnight and RED in the short column and watch AF burn.
Market Data 
Markets 
